A significant test of a daily weight loss pill revealed that it helped people eliminate books and reduce their blood sugar, making it a competitor to join the new wave of drugs that fight against obesity and diabetes.
People who took a 36 mg orforglipron pill lost an average of 7.3 kg (16 pounds) over nine months, according to the results of a phase 3 clinical trial reported by the drug manufacturer, Eli Lilly on Thursday.
The test, which registered 559 obese people with type 2 diabetes of the United States, China, India, Japan and Mexico, also noted that the daily pill reduced blood sugar, in some cases, putting them below the formal threshold of diabetes.
The test results are impatiently awaited by health researchers. Orforglipron is a daily version of a pill of a GLP-1 agonist, the drug used in successful successful weight loss injections such as Ozempic and Wegovy.
David Ricks, managing director of Eli Lilly, said: “As a pill Once practical daily, Orforglipron can provide a new option and, if approved, could be easily manufactured and launched on a large scale for use by people from around the world.”
In a statement accompanying the results, the company said that the drug met safety, tolerability, glucose control and weight loss expectations.
Although the jabs of weight loss have climbed into popularity, health officials believe that the daily versions of drug pills could allow more people to control their weight and blood sugar. In Great Britain, two thirds of adults are overweight or live with obesity and more than 5 million people suffer from type 2 diabetes.
The 40 -week trial showed that taking a daily pill of 3 mg, 12 mg or 36 mg reduced blood sugar from 1.2% to 1.5%. During the same period, participants saw their weight drop on average by 4.5% on the 3 mg pill, 5.8% on the 12 mg and 7.6% pill on the 36 mg pill.
After promoting the newsletter
The results will be presented at a meeting of the American Diabetes Association in June before the publication in a review evaluated by peers. The company said it would request approval to market the drug management later this year and for type 2 diabetes next year.
Naveed Sattar, cardiometabolic professor of medicine at the University of Glasgow, said: “These are important results. Having new oral agents that lower glucose but also significantly the weight beyond the levels observed with most tests. »»
